Published: 5 September 2015
Author(s): Pier Mannuccio Mannucci, Alessandro Nobili
Section: Commentary

In the frame of the Atrial Fibrillation Registry for Ankle–Brachial Index Prevalence Assessment-Collaborative Italian Study (ARAPACIS) involving 93 Internal Medicine wards, Pignatelli et al. [1] conducted a questionnaire survey that, in addition to other questions, asked on the drugs of choice for prophylaxis of cardioembolism in patients with non-valvular atrial fibrillation (AF). Aspirin was chosen by 9% of the respondents, whereas oral anticoagulants were chosen by as many as 91% of the responders, 55% preferring vitamin K antagonists (VKAs) and 36% the non-vitamin K oral anticoagulants (NOACs) (of which dabigatran, rivaroxaban and apixaban are licensed in Italy).

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness